Facial Emotion Recognition in Insomnia and Emotional Regulation
Launched by UNIVERSITY HOSPITAL, ANGERS · Feb 1, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well people with chronic insomnia can recognize emotions on faces compared to individuals without insomnia. Chronic insomnia affects many people, leading to sleep difficulties that can impact daily life and social interactions. The researchers want to understand if those with insomnia have trouble recognizing emotions, which could help improve treatment options.
To participate in the study, you need to be between 18 and 65 years old and either have chronic insomnia (with a specific score showing the severity of the condition) or belong to a control group without insomnia. Participants will complete tests to see how they recognize emotions, both under controlled conditions and using eye-tracking technology that measures attention. The study is not yet recruiting participants, but the findings could provide valuable insights into how insomnia affects social skills and lead to better therapies focused on emotional understanding and regulation.
Gender
ALL
Eligibility criteria
- • Pre-inclusion criteria
- • Age between 18 and 65
- • Signed consent to participate in the study
- • Person affiliated to or benefiting from a social security scheme
- • For insomnia group: known insomnia (patient treated for insomnia)
- Inclusion criteria:
- • Insomnia group: ISI \>14 (between 15 and 28 = clinical insomnia)
- • Control group: ISI \< 8 (between 0 and 7 = no insomnia)
- • Non-pre-inclusion criteria
- • Known psychiatric disorders (Characterized depressive episode, Bipolar disorder, Schizophrenia and other delusional disorders, Specified anxiety disorder (social anxiety, generalized anxiety disorder), Obsessive-compulsive disorder (OCD), Eating disorders, Neurodevelopmental disorders (ASD, ADHD), Active addictive disorders (excluding tobacco), ...)
- • Taking antidepressant, neuroleptic or thymoregulator medication
- • Taking a benzodiazepine with a long half-life (\>12 hours)
- • Condition requiring hospitalization in the month preceding the study
- • Known sequelae or progressive neurological disease
- • Known significant ophthalmological condition
- • Pregnancy or breast-feeding
- • Person deprived of liberty by judicial or administrative decision
- • Person subject to a legal protection measure
- • Person under psychiatric care without consent
- • For control group: no known insomnia
- Non-inclusion criteria :
- • - Psychiatric disorders identified during psychiatric interview
About University Hospital, Angers
The University Hospital of Angers is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to investigate new therapeutic approaches and improve patient outcomes. Committed to excellence in patient care and medical education, the University Hospital of Angers collaborates with a network of researchers and healthcare professionals to facilitate groundbreaking studies across various medical fields, ensuring rigorous adherence to ethical standards and regulatory compliance. Through its clinical trial initiatives, the institution aims to contribute significantly to the advancement of medical knowledge and the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported